Nexviazyme

Genzyme’s Nexviazyme gets US FDA Approval for Pompe disease treatment

Sanofi’s Genzyme has recently secured the FDA approval for Nexviazyme (avalglucosidasalfa-ngpt). It has received Breakthrough Therapy and Orphan Drug Designations. This willadd more scope for treating patients with late-onset Pompe disease, a rare genetic condition. Nexviazyme is the third innovative drug to be launched by Sanofi for the Pompe disease management. Myozyme and Lumizyme are…